By enabling the introduction of precise single-nucleotide changes at virtually any locus, CRISPR/Cas genome editing technology has dramatically expanded the capacity to generate model systems relevant to the study of human disease. However, these applications often rely on an endogenous cellular mechanism known as homology-directed repair (HDR) that occurs at relatively low frequencies in iPSCs. Consequently, reliable detection of precise editing in mixed populations and identification of successfully edited clones can prove challenging for researchers.

In this on-demand webinar, Dr. Montse Morell discusses the challenges associated with engineering SNPs in iPSCs, and presents a novel assay that she developed to enable rapid, reliable screening for precise single-nucleotide edits in bulk-edited or clonal populations.

About the presenter

Montse Morell, PhD

Scientist III, Takara Bio USA, Inc.

Dr. Morell received her BS degree with honors in Chemistry from Universitat Autonoma de Barcelona in 2003. In 2008 she completed her PhD in Biotechnology at the same university. Her thesis work focused on the development of protein reporters to study in vivo protein interactions and aggregation. Afterward, she performed her postdoctoral work at Stanford University where she developed fluorescent probes to detect the activity of metaloproteases in vivo. Since 2013 she has been working at Takara Bio USA, Inc. as a scientist and has played an instrumental role in the development of products related to genome engineering using CRISPR/Cas9.